Global Anti-Obesity Prescription Drugs Market

Anti-Obesity Drugs Market valued at USD 5.9 Bn in 2024, growing at 16.5% CAGR to reach USD 20.02 Bn by 2032. Driven by GLP-1 therapies and rising obesity rates.

Anti-Obesity Drugs Market Overview

Anti-obesity drugs are designed to aid weight loss by suppressing appetite, inhibiting fat absorption, or altering metabolic pathways.

Anti-obesity drugs market is growing due to the escalating global obesity epidemic caused by sedentary lifestyles and poor dietary habits, with over 1.8 billion overweight adults (WHO). Key drivers include rising obesity related comorbidities and accelerated FDA approvals for next-generation drugs like GLP-1 agonists. Demand outpaces supply due to manufacturing constraints and high R&D costs, by their innovation in oral formulations aims to bridge gaps.

North America dominates, attributed to high obesity rates and healthcare spending, while Asia Pacific emerges as the fastest-growing region thanks to its increasing disposable income and awareness. Leading players are Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) leverage strong pipelines and strategic partnerships to maintain dominance. End users primarily rely on retail pharmacies, though telehealth platforms are disrupting access.

The report covered the Anti-Obesity Drugs Market dynamics, structure by analyzing the market segments and projecting the Anti-Obesity Drugs Market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the Anti-Obesity Drugs Market.To know about the Research Methodology :- Request Free Sample Report

Global Anti-Obesity Drugs Market Dynamics

The rising prevalence of obesity worldwide is the major factor to Drive the Anti-Obesity Drugs market growth

The anti-obesity drugs market is expected to rise due to the rising cases of obesity and overweight among patients worldwide as a result of inactive lifestyles and bad eating habits. The leading players in the industry are also undergoing product creation and finding market approvals as a result of the rise in the global obesity population. In 2023, Novo Nordisk allied with Evotec AG to discover and produce drug molecules to treat a variety of metabolic disorders, such as obesity, diabetes, and other related illnesses. The increasing need for medicines that have long-term effects is expected to create enormous opportunities for market vendors to develop new products. This factor is expected to eventually aid the market growth.

The rising prevalence of obesity, as well as type II diabetes, has prompted many market analysts and vendors to conduct studies on drugs that can treat both obesity and type II diabetes. MED10382 by AstraZeneca and Bimagrumab by Novartis are two of the medicines being tested for obesity and type II diabetes.

However, drug side effects and the lack of combination therapy are expected to limit the market's growth. Along with this, the market for anti-obesity drugs is expected to be hampered by the rising acceptance of alternative treatments such as gyms, exercise spas, treatments to minimise obesity, patient compliance for surgical procedures, and a high change in diet plan. Furthermore, the launch of new anti-obesity drugs, as well as untapped opportunities in emerging markets, would boost demand growth over the forecast period.

The report has profiled fifteen key players in the market from different regions. However, the report has considered all market leaders, followers, and new entrants with investors while analyzing the market and estimating the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and a report has come up with recommendations for a future hot spot in the APAC region.

Global Anti-Obesity Drugs Market Segment Analysis

The Global Anti-Obesity Drugs Market is segmented on the basis of Mechanism of Action, Drug Type, and Distribution Channel.

Based on Drug Type, the Prescription Drugs segment is expected to hold the dominant market share during the forecast period. The easy availability of therapeutically effective anti-obesity drugs in the market is credited with the segment's rapid growth. The increasing consumption of junk food is causing global population health to deteriorate, leading to an increase in the prevalence of obesity, especially in developing countries.

Based on Distribution Channel, the retail pharmacies dominate the Anti-Obesity Drugs Market, accounting for the largest share at 42%. This is primarily due to their widespread accessibility, convenience, and trusted presence in both urban and rural areas. Consumers often prefer retail pharmacies for quick, in-person consultations and immediate medication availability. Additionally, the growing number of prescription-based anti-obesity drugs encourages purchases through licensed retail outlets, supporting this segment's continued dominance.

Global Anti-Obesity Drugs Market Regional Insights:

North America is expected to account for the largest market share during the forecast period.

North America is expected to hold a dominant market share during the forecast period, owing to the increase in the obese population and high healthcare expenditure are the primary factors driving the market's growth. The Centers for Disease Control and Prevention (CDC) states that adult obesity prevalence is growing owing to current circumstances of work from home, less physical activity, and financial and other stress among the adult population, which contributes to the market growth in the region.

The Asia Pacific is expected to witness the highest growth during the forecast period.

The factors contributing to the market growth in the region are the rising consumer disposable income, the rise in healthcare expenses, and the increasing prevalence of obesity and both type I and type II diabetes. Also, the increasing demand for drugs and rising awareness about anti-obesity drugs in Asia Pacific countries such as India, China, and South Korea will contribute to the region's anti-obesity drugs market growth.

Anti-Obesity Drugs Market Competitive Landscape

Anti-obesity drugs market features a competitive landscape dominated by key players like Pfizer Inc., Novo Nordisk A/S, Eli Lilly and Company, Vivus LLC, and Currax Pharmaceuticals LLC. Companies lead the market through strategic innovation, strong R&D investment, and expanding drug portfolios. Novo Nordisk has gained prominence with semaglutide (Wegovy), a GLP-1 receptor agonist that has shown significant weight loss efficacy and expertise in diabetes management.

Eli Lilly is advancing with tirzepatide (Zepbound), a dual GIP/GLP-1 agonist, capitalising on its success in metabolic disorders. Pfizer focuses on oral anti-obesity drugs, aiming for patient convenience over injectables, while Vivus (Qysmia) and Currax (Contrave) emphasise combination therapies targeting multiple pathways for weight loss. Companies maintain dominance by their strong clinical trial result, strategic partnerships, and marketing, addressing the growing global obesity epidemic.

Novo Nordisk and Eli Lilly benefit from an established reputation in metabolic health and faster market penetration compared to smaller competitors. Rise of biotech firms and increasing mergers in the obesity drug space further intensify competition, pushing innovation in next-generation therapies.

Anti-Obesity Drugs Market Key Trends

1) GLP-1 Agonist Dominance
Drugs like Semaglutide (Wegovy/Ozempic) and Tirzepatide (Zepbound/Mounjaro) are revolutionizing obesity treatment due to their strong efficacy (15-20%+ weight loss) and additional benefits like blood sugar control. Their success has spurred R&D into next-generation GLP-1-based therapies, making them the gold standard in the market.

2) Increased FDA Approvals & Pipeline Growth
Regulatory agencies are accelerating approvals for novel anti-obesity drugs (e.g., Retatrutide, CagriSema) as demand surges. The robust clinical pipeline includes oral formulations and triple-hormone agonists, expanding options beyond injectables.

3) Rising Obesity Prevalence & Awareness
With over 1 billion obese adults globally (WHO 2024), the need for pharmacological interventions is growing. Public health campaigns and celebrity endorsements (e.g., Oprah Winfrey’s GLP-1 advocacy) are reducing stigma and boosting adoption.

4) Telemedicine & DTC (Direct-to-Consumer) Models
Startups like Hims & Hers and WeightWatchers Clinic are leveraging telehealth to prescribe anti-obesity drugs, improving access. Subscription-based models and home delivery services are disrupting traditional pharmacy channels.

Anti-Obesity Drugs Market Recent Development

1. On July 27, 2023, Eli Lilly (USA) announced positive Phase III results for Zepbound (tirzepatide), boosting its position in the anti-obesity drugs market with strong efficacy data from the SURMOUNT‑3 and SURMOUNT‑4 trials.

2. On April 15, 2025, Pfizer (USA) withdrew its oral GLP‑1 candidate, danuglipron, due to safety concerns, marking a setback in its strategy within the anti-obesity drugs market.

3. On June 20, 2025, Novo Nordisk (Denmark) revealed early Phase Ib trial data showing that its dual agonist amycretin led to 24.3% weight loss via injection and 13.1% via oral delivery.

Global Anti-Obesity Drugs Market Scope: Inquire before buying

Anti-Obesity Drugs Market, by region

North America (United States, Canada and Mexico)
Europe (United Kingdom, France, Germany, Italy, Spain, Sweden, Russia, Rest of Europe)
Asia Pacific (China, Japan, South Korea, India, Australia, Malaysia, Thailand, Vietnam, Indonesia, Philippines, Rest of APAC)
Middle East and Africa (South Africa, GCC, Nigeria, Egypt, Turkey, Rest of MEA)
South America (Brazil, Argentina, Colombia, Chile, Peru, Rest of South America)

Anti-Obesity Drugs Market Key Players are:

North America
1. Pfizer Inc. (USA)
2. Eli Lilly and Company (USA)
3. Vivus LLC (USA)
4. Currax Pharmaceuticals LLC (USA)
5. Arena Pharmaceuticals Inc. (USA)
6. Rhythm Pharmaceuticals Inc. (USA)
7. Orexigen Therapeutics Inc. (USA)

Europe
8. Novo Nordisk A/S (Denmark)
9. F. Hoffmann La Roche Ltd (Switzerland)
10. GlaxoSmithKline plc (United Kingdom)
11. AstraZeneca PLC (UK/Sweden)
12. Norgine Pharmaceuticals Ltd. (UK/Netherlands)
13. Sanofi S.A. (France)
14. Bayer AG (Germany)
15. Novartis AG (Switzerland)
16. Zealand Pharma A/S (Denmark)

Asia Pacific
17. Takeda Pharmaceutical Company Ltd. (Japan)
18. Sun Pharmaceutical Industries Ltd. (India)
19. Intas Pharmaceuticals Ltd. (India)
20. Teijin Pharma (Japan)
21. Cipla Ltd. (India)
22. Torrent Pharmaceuticals Ltd. (India)
23. Zydus Lifesciences (India)
24. Glenmark Pharmaceuticals (India)

Middle East & Africa
25. Teva Pharmaceutical Industries Ltd. (Israel)
26. Gulf Pharmaceutical Industries (UAE)
27. Saudi Pharmaceutical Industries & Medical Appliances (Saudi Arabia)
28. Jordanian Pharmaceutical Manufacturing Company (Jordan)

South America
29. CFR Pharmaceuticals S.A. (Chile)

FAQ:

1] What are the leading market players active in the Anti-Obesity Drugs Market?
Ans. Top players in the Anti-Obesity Drugs Market include Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, AstraZeneca PLC, Takeda Pharmaceutical Company Ltd., and Sanofi S.A.

2] What was the market in the Anti-Obesity Drugs Market in 2024?
Ans. The market size in the Anti-Obesity Drugs Market in 2024 is USD 5.9 billion.

3] Which region is expected to hold the highest share in the Global Anti-Obesity Drugs Market?
Ans. The North America region is expected to hold the highest share in the Anti-Obesity Drugs Market.

4] What is the growth rate of the Global Anti-Obesity Drugs Market?
Ans. The Global Anti-Obesity Drugs Market is growing at a CAGR of 16.5% during the forecasting period 2025-2032.

5] What is the scope of the Global Anti-Obesity Drugs market report?
Ans. Global Anti-Obesity Drugs Market report helps with the PESTEL, Porter's, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.